TuHURA Bolsters Pipeline, Burns Cash in 2025
Event summary
- TuHURA Biosciences reported $20.5 million in R&D expenses for 2025, up from $13.3 million in 2024, with pro forma expenses including Kineta at $22.1 million.
- The company raised $21.2 million through registered direct offerings and private placements in 2025, ending the year with $3.6 million in cash.
- TuHURA acquired rights to VISTA inhibiting antibody TBS-2025 from Kineta for $10.5 million.
- Enrollment for the Phase 3 IFx-2.0 trial in Merkel Cell Carcinoma is now anticipated to be completed in mid-2027.
- TuHURA appointed Craig Tendler, M.D. as a strategic advisor to oversee clinical development, effectively acting as a Chief Medical Officer.
The big picture
TuHURA's strategy of acquiring promising assets like TBS-2025 reflects a common approach in immuno-oncology – leveraging existing pipelines to accelerate development. However, the company’s substantial cash burn and reliance on capital markets highlight the financial pressures facing smaller biopharma companies pursuing complex clinical trials. The appointment of a de facto CMO suggests a focus on streamlining clinical operations, but the delayed enrollment timeline indicates potential challenges ahead.
What we're watching
- Cash Runway
- With a significant cash burn and limited near-term revenue, TuHURA’s ability to secure additional funding will be critical to sustaining its development programs, particularly as the Phase 3 trial progresses.
- Clinical Execution
- The delayed enrollment timeline for the Phase 3 trial raises questions about operational efficiency and potential setbacks in achieving accelerated approval for IFx-2.0.
- Pipeline Diversification
- The success of the ADC program, and its ability to generate data and attract investment, will be key to diversifying TuHURA’s pipeline beyond its reliance on IFx-2.0 and TBS-2025.
Related topics